Drug intelligence / Profile preview

Chlormix

Development stage: Unknown
Lead developer: Jainson Biotech
Modality: Small Molecules
Administration: Ophthalmic

Overview

Chlormix is a Jainson Biotech ophthalmic antibacterial ointment containing chloramphenicol 1.0% w/w and polymyxin B sulphate 10,000 units. It is marketed for bacterial ocular infections, including blepharitis, conjunctivitis, bacterial keratitis, and bacterial corneal ulcer. Chloramphenicol inhibits bacterial protein synthesis, while polymyxin B disrupts susceptible bacterial cell membranes. ([jainsonbiotech.com](https://www.jainsonbiotech.com/chlormix.php))

Brand names: Chlormix

Targets

PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on Chlormix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chlormix.

Explore the full profile